Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer

Inclusion Criteria:

* Cytologic of histologic proof of pancreatic ductal carcinoma
* No evidence of metastatic disease
* 18 years of age or older
* ECOG Performance Status of 0 or 1 - Lab values as outlined in the protocol

Exclusion Criteria:

* Tumors in the body or tail of the pancreas
* Hepatic or peritoneal metastases detected by imaging or laparoscopy prior to chemoradiation
* Serious concomitant systemic disorders incompatible with the study, such as significant cardiac or pulmonary morbidity, ongoing infection as manifested by fever
* Pregnant or lactating women
* Life expectancy of \< 3 months
* Serious, uncontrolled, concurrent infection (s)
* Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor
* Clinically significant cardiac disease or myocardial infarction within the last 12 months
* Other serious uncontrolled medical condition that the investigator feels might compromise study participation
* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome
* Known, existing uncontrolled coagulopathy
* Any prior fluoropyrimidine therapy
* Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to a 5-fluorouracil or known DPD deficiency
* Participation in any investigational drug study within 4 weeks preceding the start of the study
* History of uncontrolled seizures, central nervous system disorders or psychiatric disability
* Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
* Patients on cimetidine